Objective: To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. Methods: Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. Results: In all, 188 (48%) questionnaires were returned. In total, 72/128 (56%) of the urologist respondents and 58/60 (97%) of the oncologist respondents perform routine radical prostate treatment. Among 43 (60%) of the urologist, 40 (69%) recommended adjuvant treatment, which could be radiotherapy, hormonal treatment or combined hormonal and radiation treatment. There is no significant difference between the modality of treatment recommended. The poor prognostic factors that would influence the decision to offer adjuvant treatment include a detectable postoperative PSA, seminal vesicle involvement, positive margins, Gleason score 48 and pathological T3. With regard to the choice of hormonal treatment, most urologists preferred antiandrogens, whereas most oncologists prefer lutienising hormone releasing hormone (LHRH) analogue (P ¼ 0.03). Regarding salvage treatment, there is a wide variation in the PSA threshold and number of PSA rises before initiation of investigations and treatment. Significantly more urologists recommended salvage radiotherapy (P ¼ 0.02), whereas oncologists recommended combined hormonal radiation therapy (P ¼ 0.03). There is a wide variation of practice regarding the duration of hormonal treatment, the type of investigations initiated, range of radiotherapy doses and treatment volumes. Conclusion: There is a wide variation in practice among UK clinicians.
Introduction
The number of radical prostatectomies in the UK is increasing rapidly, with a 20-fold increase between 1991 and 1999. This is mainly due to the increasing numbers of prostate cancers diagnosed at an earlier stage and at younger age of presentation with the widespread availability of PSA assays. 1 PSA failure after RP is unfortunately a common problem, arising in about 20-40% of men within 5 y of surgery. 2 Pathological characteristics such as positive margins, high Gleason grade, seminal vesicle involvement and detectable PSA after surgery are predictive of disease recurrence. 3 The natural history of disease relapse after prostatectomy is that of development of metastasis and eventually death, usually over a period of several years. 4 The optimal treatment of patients whose PSA is rising after radical prostatectomy (salvage treatment) or treatment of patients who are at high risk of relapse based on histological features (adjuvant treatment) is uncertain. There is no clear evidence from randomised controlled trials to guide decision-making. The selection of patients for treatment is often difficult as not all patients with poor histological prognostic factors will relapse. Furthermore, those who have a rising PSA after prostatectomy will not always develop overt clinical relapse. Majority of the data in this setting is from retrospective studies, which are open to selection bias and are of limited value. The timing of intervention is also debatable as intervention causes morbidity. There is also the issue of anxiety generated by expectant management in the presence of rising PSA. To facilitate planning of studies in relation to these issues we have carried out a survey of current practice of urologists and radiation oncologists to determine the current practice in the UK. 
Method

Results
A total of 390 questionnaires were sent out and 188 were returned (48%). There were 128 responses from urologists (44% out of 292 surveys sent out) and 60 responses from oncologists (61% out of 98 surveys sent out). Of the 128 replies from urologists, 72 (56%) routinely performed radical prostatectomy. Among the oncologists, 58 (97%) stated that they routinely offer radical prostate cancer treatment (ie, treatment with a curative intent). Further analysis was limited to those who routinely perform radical treatment.
Adjuvant treatment
In a patient with poor prognostic factors after radical prostatectomy, 43 (60%) of urologists and 40 (69%) of radiation oncologists recommend adjuvant treatment. There is no significant difference between the urologists and the oncologists (P ¼ 0.28). Of the urologists who recommend adjuvant treatment, 72% used radiotherapy alone, 42% hormonal treatment alone and 35% combined hormonal and radiation therapy. 37% of the urologist recommended more than one of the above options depending on the circumstances. On the other hand, 34% of radiation oncologists recommend adjuvant radiotherapy alone, 16% recommend hormonal treatment alone and 34% recommend combined hormonal and radiation therapy and 19% of radiation oncologists recommended more than one of the above options depending on the circumstances (see Figure 1 ). There was no significant difference in the type of adjuvant treatment recommended between urologists and oncologists (P ¼ 0.12), with majority of clinicians recommending adjuvant radiotherapy alone. The distribution of poor prognostic factors that would influence the decision to offer adjuvant treatment amongst urologists is shown in Figure 2 , and among radiation oncologists in Figure 3 . As a sole trigger factor, 70% of urologists consider a detectable postoperative PSA alone, 30% consider seminal vesicle involvement alone, while only 23% would consider positive margins alone as an important deciding factor for adjuvant treatment. Also, 44% of urologist would consider positive margin, 30% Gleason score above 8, 28% seminal Adjuvant and salvage treatment after radical prostatectomy LW Lee et al vesicle involvement, 25% pathological T3 disease and 19% persisting postoperative PSA as factors considered in combination for adjuvant treatment. As a sole poor prognostic factor, 60% of radiation oncologists considered a detectable postoperative PSA alone, 28% Gleason score above 8, 28% positive margins and 20% seminal vesicle involvement alone as deciding factors for adjuvant treatment. Also, 58% of radiation oncologists would consider positive margins, 45% pathological T3 disease 40% Gleason score above 8, 32% seminal vesicle involvement and 28% persisting postoperative PSA as factors considered in combination for adjuvant treatment.
With regard to the choice of hormonal treatment, most urologists preferred antiandrogens, whereas most oncologists prefer lutienising hormone releasing hormone (LHRH) analogue (P ¼ 0.03). There was a marked variation on the recommended duration of hormonal treatment, both as a sole agent (intermittent to lifelong) and in combination with radiotherapy (3 months to 3 y) in both urologists and radiation oncologists (see Table 1 ).
Salvage treatment
In recommending salvage treatment, the sensitivity of PSA assays was an important factor. The distribution of respondents' laboratory PSA sensitivities is shown in Figure 4 . The PSA threshold for which clinicians would initiate investigation and treatment is shown in Figure 5 . In addition, 26% of urologists would also initiate investigations or treatment at two consecutive PSA rises, and 35% at three consecutive rises. Also, 26% of urologists uses PSA alone, 33% uses the number of PSA rises alone and 35% uses both the PSA value and the number of PSA rises as a trigger to initiate investigations and treatment. On the other hand, 22% of radiation oncologists would initiate investigation or treatment at two consecutive PSA rises, and 52% at 3 consecutive rises. Amongst the radiation oncologists, 21% uses a PSA value alone, 46% uses the number of PSA rises alone and 33% uses both the PSA value and the number of PSA rises as a trigger to initiate investigation or treatment.
The investigations recommended are shown in Figure 6 . One urologist uses PSA doubling time (PSADT) alone and no other investigations. Details of investigations were broadly similar between urologists and oncologists with approximately one-third recommending bone scan and one-half cross-sectional imaging. The use of Prostascint scan was recommended by one oncologist.
The types of salvage treatment recommended are shown on Figure 7 . Significantly more urologists recommended salvage radiotherapy alone (P ¼ 0.02), and significantly more radiation oncologists recommended salvage combined hormonal treatment and radiotherapy (P ¼ 0.03). One urologist recommended salvage cryoablation as the sole option for salvage. 
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There is similar variability of the duration of hormonal treatment, both as a sole modality and in combination with radiation treatment. As a sole treatment on relapse, 69% of urologists and 50% of oncologists would suggest lifelong treatment, and 19% of urologists suggested intermittent hormonal treatment. In combination with radiotherapy a wide range of treatment duration was given by both urologists and clinical oncologist, with the majority ranging from 3 months to 3 y.
Among the radiation oncologists there is a wide range of radiotherapy doses used (see Table 2 ). The majority of clinicians used 64 Gy (48% of those offering adjuvant treatment, 44% of those offering salvage treatment). 30% used hypofractionation for adjuvant treatment, 33% used hypofractionation for salvage. Some radiation oncologists used doses above 64 Gy (12% of those offering adjuvant treatment, 12% of those offering salvage treatment). One oncologist mentioned that the fraction size will depend on the rectal dose volume histogram. All clinical oncologist use CT conformal radiotherapy planning. There is variability of radiotherapy volumes (see Figure 8) , with the largest group (40%) treating between 500 and 599cm.
3 16 (28%) clinical oncologist were unable to give an estimated planning treatment volume, as it was not routinely calculated in their institutions.
Discussion
This survey provides a snapshot of current practice amongst UK urologists and oncologists in relation to adjuvant as well as salvage treatment for patients who have had radical prostatectomy for prostate cancer. Although the response rate was approximately half, questionnaires were returned by clinicians with a particular interest in the issue and who therefore form an appropriate cross-section of the current practice. The number of urologists who practise radical prostatectomy in the UK is very small and we feel that the number of respondents in this survey who practice radical prostatectomy is representative of the community of urologists who perform this procedure.
Similar surveys of practices in other countries have been published. [5] [6] [7] [8] Most show that there is a diversity of opinion regarding adjuvant and salvage postprostatectomy management. Ornstein et al 5 reported the survey results of 1050 American Urological Association members, the largest survey on the subject of radical prostatectomy failure. For the evaluation of men with rising PSA after prostatectomy, 98% used digital rectal examination, 68% used bone scan, 54% used transrectal ultrasound without biopsy, 11% used monoclonal antibody scan and 5% used MRI. To treat documented local recurrence, 81% recommended radiotherapy, 7% recommended hormonal treatment, 5% combined androgen ablation and 6% recommended observation only. To treat PSA only recurrence, 54% recommended observation only, 16% combined androgen ablation, 15% hormonal treatment, 13% radiotherapy.
Johnson et al 6 reported a small survey of 23 US military urologists. With regard to salvage radiotherapy, three factors were important: namely: T-stage, time since surgery and PSA velocity. They felt that PSA velocity and nodal status are the most two most important factors in starting hormonal treatment postprostatectomy. Mean values of PSA cut off to institute salvage radiotherapy was between one and two except for patients aged 470, positive nodes or poor performance status.
Duchesne et al 7 reported on a survey of Australian clinicians (56 urologists, 28 radiation oncologists and 24 medical oncologists). For postoperative PSA relapse, most (55%) favoured salvage radiotherapy to the prostate bed, but significantly more radiation oncologist recommended it. The level of PSA prior intervention varied widely, ranging from 0.8 to 100 ng/ml in the postoperative setting. Clinicians also tended to intervene earlier for a high PSA doubling rate. Of those who indicated a preference, two-thirds recommended a LHRH analogue. Adjuvant and salvage treatment after radical prostatectomy LW Lee et al
The result of our survey suggests that many more UK urologists and radiation oncologists are willing to consider adjuvant and salvage treatment, although it is difficult to compare this with the above mentioned surveys, as those surveys reflect the practice of clinicians in different countries and in different eras. However, it is clear that majority of UK clinicians would recommend radiotherapy as either adjuvant or salvage treatment. As a consequence there are significant implications for the demand of radiotherapy services considering the increasing number of radical prostatectomies undertaken and postsurgical PSA relapse. This survey will need to be taken into account in future medical healthcare planning.
Although many UK clinicians would recommend adjuvant and salvage treatment after radical prostatectomy, the role of treatment remains contentious. The preliminary results of the Early Prostate Cancer program evaluating the role of adjuvant bicalutamide are too preliminary to draw any conclusions. 9 A small trial of 98 people 10 comparing adjuvant androgen ablation in node positive patients with selective salvage treatment showed evidence of improved overall survival, prostate cancer-specific survival and progression-free survival which are statistically significant. Clinicians should, however, be cautious with the use of antiandrogens as an adjuvant treatment in view of the recent report of increased risk of death with bicalutamide in early untreated prostate cancer. 11 Several retrospective series have shown that adjuvant treatment and salvage treatment with radiotherapy are associated with a reasonable biochemical disease-free survival. Two multicentre trials evaluating the role of adjuvant radiotherapy (EORTC 22911, SWOG 8794) have been closed but the results are still awaited. The preliminary results of EORTC 22911 was presented at ASTRO annual meeting in 2004. A total of 1005 patients with pT3N0 prostate cancer were randomised to receive adjuvant radiotherapy versus surveillance. There is significant improvement in PSA relapse-free survival and local control but no difference in distant metastases and overall survival. 12 There is an ongoing three-armed adjuvant trial, RTOG P-0011/NCIC PR9 comparing radiation, hormones or combination hormonal and radiotherapy, which is slow to accrual. The RTOG 96-01 trial, which investigates the role of hormonal treatment in addition to irradiation in the setting of PSA elevation following radical prostatectomy, is now closed. The results of this trial are awaited to confirm if the addition of hormonal treatment improves outcome. EORTC 30943, (now closed) evaluated adjuvant hormonal treatment after definitive treatment for localised prostate cancer, RTOG 96-08 (now closed) evaluated the role of radiotherapy in addition to total androgen suppression in node positive prostate cancer, whereas the RTOG 99-02 currently open is evaluating the role of adjuvant chemotherapy after combined hormonal radiotherapy for high-risk prostate cancer. For salvage treatment, the RTOG 0014 is now evaluating the role of chemotherapy in addition to androgen ablation in those with PSA failure after definitive local surgical or radiotherapy treatment. Until the results of these trials become available, it will remain difficult to achieve a consensus with regards to adjuvant or salvage treatment.
The results of this survey show that there is a wide variation in practice amongst UK clinicians. Until the results of well-constructed trials are available, the practice pattern is likely to remain variable.
